Gain Therapeutics receives regulatory approval to launch international Phase 2 trial of oral Parkinson's treatment GT-02287

A new experimental pill designed to alter the underlying biological progression of Parkinson's has received clearance from the US Food and Drug Administration to move into Phase 2 clinical trials. The oral therapy, known as GT-02287 and developed by Gain Therapeutics, aims to prevent the formation of toxic protein clumps that destroy brain cells. This regulatory milestone paves the way for a mid-stage trial scheduled to launch in the third quarter of 2026, with testing expanding across sites in the United States, Europe, and Australia. Unlike standard treatments that only mask symptoms, this new drug candidate targets the cellular plumbing system of the brain. It acts as a specialized guide that restores the function of a vital enzyme called GCase. When this enzyme misfolds due to genetic mutations or age-related stress, waste products pile up, causing a protein called alpha-synuclein to form toxic aggregates. By keeping the enzyme properly folded and functional, the pill has successfully reduced protein clumping, brain inflammation, and nerve cell death in preclinical models, which translated into recovered motor skills and complex behaviors during lab studies. The step into Phase 2 testing follows encouraging data from earlier trial phases conducted in Australia. Healthy volunteers and people with Parkinson's tolerated the drug well during five months of continuous use. Beyond safety, early biomarker data showed that the pill effectively hit its target, triggering an average 81% reduction in a harmful waste molecule within the spinal fluid of participants who started with elevated levels. Remarkably, these biological changes matched real-world physical improvements. Participants with high baseline levels of the waste molecule showed notable progress in their official motor and daily living scores by day 150 of the study. Clinical sites also tracked promising anecdotal feedback from the people taking part, who reported noticeable improvements in their sense of smell and taste, better sleep quality, and steadier balance and walking gait. The upcoming Phase 2a study will formalize these findings by evaluating both treated and untreated people in the early stages of Parkinson's, utilizing objective tracking metrics to confirm whether the therapy can truly slow or stop the condition in its tracks.